ROBERTO HEGG
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina - Docente
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
- Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T plus AI vs L plus AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE.(2017) GRADISHAR, William John; HEGG, Roberto; IM, Seock-Ah; PARK, In Hae; TJULANDIN, Sergei; KENNY, Sarah; SARP, Severine; WILLIAMS, Lisa; IZQUIERDO, Miguel A.; JOHNSTON, Stephen R. D.
- First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial(2018) RIMAWI, Mothaffar; FERRERO, Jean-Marc; HABA-RODRIGUEZ, Juan de la; POOLE, Christopher; PLACIDO, Sabino De; OSBORNE, C. Kent; HEGG, Roberto; EASTON, Valerie; WOHLFARTH, Christine; ARPINO, GraziaPurposeTo assess pertuzumab plus trastuzumab and an aromatase inhibitor (AI) in patients with human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive metastatic/locally advanced breast cancer (MBC/LABC).Patients and MethodsThe PERTAIN trial (NCT01491737) is an ongoing randomized, open-label, multicenter80 sites and eight countriesphase II trial. Patients have HER2-positive, hormone receptor-positive MBC/LABC and no prior systemic therapy with the exception of endocrine. Random assignment was 1:1 to intravenous pertuzumab (840 mg loading dose followed by 420 mg every 3 weeks) plus trastuzumab (8 mg/kg followed by 6 mg/kg every 3 weeks), and oral anastrozole (1 mg every day) or letrozole (2.5 mg every day), or trastuzumab and an AI. Induction intravenous docetaxel every 3 weeks or paclitaxel every week could be administered for 18 to 24 weeks at the investigator's discretion (decided before but given after random assignment). Primary end point was progression-free survival (PFS). Patients were stratified by whether they received induction chemotherapy and their time since adjuvant hormone therapy.ResultsOne hundred twenty-nine patients were randomly assigned per arm (February 2012 to October 2014; intent-to-treat populations); 75 in one arm and 71 in the other were chosen to receive induction chemotherapy. Stratified median PFS was 18.89 months (95% CI, 14.09 to 27.66 months) in the pertuzumab plus trastuzumab arm and 15.80 months (95% CI, 11.04 to 18.56 months) in the trastuzumab arm (stratified hazard ratio, 0.65; 95% CI, 0.48 to 0.89; P = .0070). Serious adverse events (AEs) were reported for 42 (33.1%) of 127 and 24 (19.4%) of 124 patients in the safety populations of the pertuzumab plus trastuzumab and trastuzumab arms, respectively. Rates of grade 3 AEs were 64 (50.4%) of 127 and 48 (38.7%) of 124, respectively. There were no deaths as a result of AEs.ConclusionPERTAIN met its primary PFS end point. Pertuzumab plus trastuzumab and an AI is effective for the treatment of HER2-positive MBC/LABC. The safety profile was consistent with previous trials of pertuzumab plus trastuzumab.
conferenceObject Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).(2021) MARTIN, Miguel; HEGG, Roberto; KIM, Sung-Bae; SCHENKER, Michael; GRECEA, Daniela; GARCIA-SAENZ, Jose A.; PAPAZISIS, Konstantinos; OUYANG, Quchang; LACKO, Aleksandra; OKSUZOGLU, Berna; REEVES, James Andrew; OKERA, Meena; TESTA, Laura; SHIMIZU, Chikako; WEI, Ran; FORRESTER, Tammy D.; MUNOZ, Maria; ZIMMERMANN, Annamaria H.; HEADLEY, Desiree; JOHNSTON, Stephen R. D.conferenceObject Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial.(2015) MACKEY, John Robert; LIPATOV, Oleg N.; MARTIN, Miguel; WEBSTER, Marc; HEGG, Roberto; VERMA, Sunil; VAZQUEZ, Manuel Ramos; FRESCO, Rodrigo; THIREAU, Francois; HOUE, Vincent; PRESS, Michael F.; NARASIMHAN, Ashok; DAMARAJU, SambasivaraoconferenceObject Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) after prior treatment (tx) with FUL in patients (pts) with advanced breast cancer (ABC): A real-world (RW) analysis.(2022) O'SHAUGHNESSY, Joyce; WOECKEL, Achim; PISTILLI, Barbara; HEGG, Roberto; VAHDAT, Linda T.; VUINA, Dragica; ASAD, Zvk Parisa (Fatemeh); SMITH, Timothy W.; KIM, Julia; KROP, Ian- Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): First-and second-line data from the BOLERO-4 study.(2017) CARDOSO, Fatima; VILLANUEVA, Cristian; ROYCE, Melanie; CRUZ, Felipe; DEBLED, Marc; HEGG, Roberto; TOYAMA, Tatsuya; FALKSON, Carla Isadora; JEONG, Joon; SRIMUNINNIMIT, Vichien; OZGUROGLU, Mustafa; GRADISHAR, William John; AZEVEDO, Sergio J.; ARCE, Christina H.; RIDOLFI, Antonia; LIN, Chinjune; BACHELOT, Thomas Denis
conferenceObject Overview of obesity and breast cancer in Brazil: 24 year of follow up.(2020) PEREIRA, Andrea Z.; PITITO, Bianca de Almeida; PRADO, Rogerio Ruscitto do; MATTAR, Andre; HEGG, Roberto; SHIDA, Jorge Yoshinori; GEBRIM, Luiz Henrique